CVS Outlines Ways to Tackle High-Cost Gene Therapies

January 15, 2020

CVS Health in a new white paper outlines four key approaches health plans and plan sponsors can take to help cushion the blow of high-cost gene therapies, Fierce Healthcare reports.

In its report, CVS outlines the following four steps:

  • Extending the National Medical Excellence program model;
  • Evolving the role of specialty pharmacy;
  • Value-based contracting; and
  • Financial protection programs.

To read CVS Health’s white paper, click here.

Click here to read the full report on Fierce Healthcare.

Share This Story!